The radiopharmaceutical Ga-68-PSMA-11 represents a radiopharmaceutical drug without marketing authorization for the prostate cancer diagnosis in a specific treatment program. In respect of the radiopharmaceutical technology, the difficultness of the preparation of Ga-68-PSMA-11 is comparable to that of conventional radiopharmaceuticals.